US equities
|
MU
$989.04
▼-3.88%
META
$742.96
▲+3.38%
NVDA
$226.32
▼-1.29%
SNDK
$1,487.33
▼-5.97%
SPCX
$163.42
▲+0.52%
MSFT
$541.15
▲+1.14%
AMD
$594.24
▼-2.28%
AAPL
$340.97
▲+1.29%
MU
$989.04
▼-3.88%
META
$742.96
▲+3.38%
NVDA
$226.32
▼-1.29%
SNDK
$1,487.33
▼-5.97%
SPCX
$163.42
▲+0.52%
MSFT
$541.15
▲+1.14%
AMD
$594.24
▼-2.28%
AAPL
$340.97
▲+1.29%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Articles published by Upstream Bio
Upstream Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
March 12, 2025
From
Upstream Bio
Via
GlobeNewswire
Tickers
UPB
Upstream Bio Announces Appointment of Rand Sutherland as CEO and Additions to Leadership Team
April 02, 2024
From
Upstream Bio
Via
Business Wire
Upstream Bio Initiates a Phase 2 Clinical Trial of Verekitug (UPB-101) in Severe Asthma and Doses First Patients
March 07, 2024
From
Upstream Bio
Via
Business Wire
Upstream Bio Announces Dosing of First Patients in a Phase 2 Clinical Trial of Verekitug (UPB-101) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
January 03, 2024
From
Upstream Bio
Via
Business Wire
Upstream Bio Announces Positive Phase 1b Interim Data in Asthma and Company Progress Toward Phase 2
October 24, 2023
From
Upstream Bio
Via
Business Wire
Upstream Bio Announces $200M Series B Financing to Advance UPB-101 for Allergic and Inflammatory Diseases
June 08, 2023
From
Upstream Bio
Via
Business Wire
Upstream Bio Presents New Phase 1 Clinical Data on UPB-101 at the American Thoracic Society (ATS) International Conference
May 22, 2023
From
Upstream Bio
Via
Business Wire
Upstream Bio to Present New Clinical Data from Phase 1 Study of UPB-101 at the American Thoracic Society (ATS) International Conference
May 12, 2023
From
Upstream Bio
Via
Business Wire
Upstream Bio Announces the Appointment of Marcella Ruddy, M.D., to the Board of Directors
February 07, 2023
From
Upstream Bio
Via
Business Wire
Upstream Bio Announces Clinical Advisory and Leadership Appointments
October 06, 2022
From
Upstream Bio
Via
Business Wire
Upstream Bio Announces Dosing of First Patient in a Phase 1b Clinical Trial of UPB-101 in Asthma
August 09, 2022
From
Upstream Bio
Via
Business Wire
Upstream Bio Launches with $200M Series A Financing to Advance Novel Therapeutics for Allergic and Inflammatory Diseases
June 02, 2022
From
Upstream Bio
Via
Business Wire
